These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24242363)

  • 1. The flavivirus protease as a target for drug discovery.
    Brecher M; Zhang J; Li H
    Virol Sin; 2013 Dec; 28(6):326-36. PubMed ID: 24242363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development.
    Luo D; Vasudevan SG; Lescar J
    Antiviral Res; 2015 Jun; 118():148-58. PubMed ID: 25842996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review.
    Wahaab A; Mustafa BE; Hameed M; Stevenson NJ; Anwar MN; Liu K; Wei J; Qiu Y; Ma Z
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of ten NS2B-NS3 proteases: Paving the way for pan-flavivirus drugs.
    Voss S; Rademann J; Nitsche C
    Antiviral Res; 2024 Jun; 226():105878. PubMed ID: 38582134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrosin B is a potent and broad-spectrum orthosteric inhibitor of the flavivirus NS2B-NS3 protease.
    Li Z; Sakamuru S; Huang R; Brecher M; Koetzner CA; Zhang J; Chen H; Qin CF; Zhang QY; Zhou J; Kramer LD; Xia M; Li H
    Antiviral Res; 2018 Feb; 150():217-225. PubMed ID: 29288700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies Towards Protease Inhibitors for Emerging Flaviviruses.
    Nitsche C
    Adv Exp Med Biol; 2018; 1062():175-186. PubMed ID: 29845533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.
    Lescar J; Luo D; Xu T; Sampath A; Lim SP; Canard B; Vasudevan SG
    Antiviral Res; 2008 Nov; 80(2):94-101. PubMed ID: 18674567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the NS2B-NS3 protease of tick-borne encephalitis virus with pan-flaviviral protease inhibitors.
    Akaberi D; Båhlström A; Chinthakindi PK; Nyman T; Sandström A; Järhult JD; Palanisamy N; Lundkvist Å; Lennerstrand J
    Antiviral Res; 2021 Jun; 190():105074. PubMed ID: 33872674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conformational switch high-throughput screening assay and allosteric inhibition of the flavivirus NS2B-NS3 protease.
    Brecher M; Li Z; Liu B; Zhang J; Koetzner CA; Alifarag A; Jones SA; Lin Q; Kramer LD; Li H
    PLoS Pathog; 2017 May; 13(5):e1006411. PubMed ID: 28542603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional interplay among the flavivirus NS3 protease, helicase, and cofactors.
    Li K; Phoo WW; Luo D
    Virol Sin; 2014 Apr; 29(2):74-85. PubMed ID: 24691778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. West Nile Virus NS2B/NS3 protease as an antiviral target.
    Chappell KJ; Stoermer MJ; Fairlie DP; Young PR
    Curr Med Chem; 2008; 15(27):2771-84. PubMed ID: 18991636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.
    Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R
    Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug design for flavivirus proteases: what are we missing?
    Poulsen A; Kang C; Keller TH
    Curr Pharm Des; 2014; 20(21):3422-7. PubMed ID: 24001226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of cis and trans activity of the Flavivirus NS2B-NS3 protease.
    Bera AK; Kuhn RJ; Smith JL
    J Biol Chem; 2007 Apr; 282(17):12883-92. PubMed ID: 17337448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.
    Martinez AA; Espinosa BA; Adamek RN; Thomas BA; Chau J; Gonzalez E; Keppetipola N; Salzameda NT
    Eur J Med Chem; 2018 Sep; 157():1202-1213. PubMed ID: 30193218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease.
    Zephyr J; Rao DN; Johnson C; Shaqra AM; Nalivaika EA; Jordan A; Kurt Yilmaz N; Ali A; Schiffer CA
    Bioorg Chem; 2023 Feb; 131():106269. PubMed ID: 36446201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of dengue virus protease expression plasmid and in vitro protease assay for screening antiviral inhibitors.
    Lai H; Teramoto T; Padmanabhan R
    Methods Mol Biol; 2014; 1138():345-60. PubMed ID: 24696347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.
    Lin KH; Ali A; Rusere L; Soumana DI; Kurt Yilmaz N; Schiffer CA
    J Virol; 2017 May; 91(10):. PubMed ID: 28298600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional determinants of NS2B for activation of Japanese encephalitis virus NS3 protease.
    Lin CW; Huang HD; Shiu SY; Chen WJ; Tsai MH; Huang SH; Wan L; Lin YJ
    Virus Res; 2007 Jul; 127(1):88-94. PubMed ID: 17467838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization of the NS2B/NS3 protease complex from seven viruses belonging to different groups inside the genus Flavivirus.
    Bessaud M; Pastorino BA; Peyrefitte CN; Rolland D; Grandadam M; Tolou HJ
    Virus Res; 2006 Sep; 120(1-2):79-90. PubMed ID: 16504332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.